Clinical Trial Update: Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia [Phase 4]

View source ↗

Summary

A Phase 4 study compared Risperdal Consta (risperidone long-acting injectable) to Abilify (aripiprazole) over two years in patients with schizophrenia to evalua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)
• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia, Psychotic Disorders | Phase 4 | Status: COMPLETED | Results posted: 2010-03-16